Latest News

Here's some of what is coming soon to NeurologyLive® this week.

The associate professor of neurology and neuroscience at the Icahn School of Medicine at Mount Sinai discussed plasma p-tau217 levels association with regional hypometabolism, cortical atrophy, and cognitive impairment in early symptomatic Alzheimer disease.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is adaptive deep brain stimulation!

Matthew Evans, BM, BCh, DPhil, consultant neurologist at Imperial College Healthcare NHS Trust, discusses emerging evidence for immune-mediated small fiber neuropathy, current diagnostic challenges, and the need for better clinical trials and biomarkers.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 19, 2026.

Phase 3 data showed a 53% reduction in relapse risk versus placebo, and ecopipam could become the first non-antipsychotic option ever approved for Tourette syndrome.

The phase 3 REVITALYZ study assessed whether once-nightly extended-release sodium oxybate can improve excessive daytime sleepiness and other core symptoms of idiopathic hypersomnia.

New preclinical findings suggest that SOM3355's combined VMAT1 inhibition, VMAT2 modulation, and β1-adrenergic antagonism may offer a differentiated approach to managing motor and neuropsychiatric symptoms in Huntington disease.

Irfan Qureshi, MD, chief medical officer at Biohaven, discusses newly reported data on opakalim, highlighting durable seizure control, favorable CNS tolerability, and the investigational agent’s potential role across multiple epilepsy syndromes.

The section chief in the Division of Pulmonary Critical Care and Sleep Medicine at West Virginia University discussed new evidence-based guidelines for sleep-disordered breathing in hospitalized patients.

Long-term phase 3 extension data showed that pitolisant was generally well tolerated and associated with sustained improvements in excessive daytime sleepiness, sleep inertia, and functional outcomes in adults with idiopathic hypersomnia for more than 2 years.

The phase 3 EMNERGIZE study evaluates whether the complement C2 inhibitor empasiprubart can improve disability and functional outcomes in adults with chronic inflammatory demyelinating polyneuropathy.

Data from phase 3 studies presented at SLEEP 2026 showed that investigational oveporexton was associated with improvements in REM sleep architecture and sleep-related symptoms in patients with NT1.